Samsung Biologics Sees Biosimilars As One Of Three Key Pillars
Follows Deal To Take Full Ownership Of Samsung Bioepis From Biogen
• By David Wallace
CDMO, biosimilars and new drugs are the three key business areas for Samsung Biologics • Source: Arturas Jasevicius / Alamy Stock Photo 
